23 February 2018
EMA/PDCO/113780/2018
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 20-23 February 2018

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

20 February 2018, 14:00- 17:00, room 3A

21 February 2018, 08:30- 19:00, room 3A

22 February 2018, 08:30- 19:00, room 3A

23 February 2018, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted.

1.3. Adoption of the minutes

The minutes of the January 2018 PDCO were adopted and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Obeticholic Acid - EMEA-001304-PIP03-17

Intercept Pharma Ltd.; NASH / NASH with Fibrosis

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

A positive opinion was adopted on D120.

2.1.2. Plazomicin Sulfate - EMEA-001639-PIP02-17

Achaogen, Inc.; Treatment of infections due to enterobacteriaceae in patients with limited treatment options, Treatment of complicated urinary tract infections

Day 120 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO at their February 2018 meeting noted the responses of the applicant to the issues raised at D90. Since all the issues were resolved the PDCO adopted a positive opinion for plazomicin in the conditions Treatment of complicated urinary tract infections and Treatment of infections due to Enterobacteriaceae enterobacteriaceae in patients with limited treatment options, with a deferral.

2.1.3. Ixazomib - Orphan - EMEA-001410-PIP02-17

Takeda Pharm A/S; Treatment of Acute Lymphoblastic Leukaemia (ALL), Treatment of Multiple Myeloma / Treatment of adult patients with Newly Diagnosed Multiple Myeloma (NDMM), Treatment of paediatric patients diagnosed with relapsed precursor B-ALL or T-ALL, Maintenance treatment of paediatric patients with newly diagnosed intermediate-risk or very high risk T-ALL/LLy

Day 120 opinion

Oncology

Summary of committee discussion:

The PDCO granted a PIP to this product for the treatment of lymphoid malignancies (excluding multiple myeloma), as described in the opinion.

2.1.4. Fevipiprant - EMEA-001315-PIP02-16

Novartis EuroPharm Ltd.; Treatment of uncontrolled persistent asthma

Day 120 opinion

Pneumology - Allergology

Summary of committee discussion:

A positive opinion was adopted on Day 120.

2.1.5. Influenza virus H1 haemagglutinin / influenza virus H3 haemagglutinin /influenza virus haemagglutinin from strain B Victoria lineage / influenza virus haemagglutinin from strain B Yamagata lineage (expressed as virus-like particle [VLP]) - EMEA-002220-PIP01-17

Medicago Inc.; For active immunization of persons six months of age and older for the prevention of influenza caused by influenza virus subtypes A and type B covered by the vaccine.

Day 120 opinion

Vaccines

Summary of committee discussion:

As all the issues were thus solved satisfactorily the PDCO adopted a positive opinion on the paediatric plan proposed by the applicant.

2.1.6. Rosuvastatin / ezetimibe - EMEA-001344-PIP02-17

Zentiva, k.s.; Prevention of Cardiovascular Events

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO's views expressed at day 30 were re-discussed and endorsed.
Based on the assessment of this application, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for ezetimibe / rosuvastatin for all subsets of the paediatric population (0 to 18 years of age) in the condition "prevention of cardiovascular events" on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.7. Humanized recombinant IgG4 anti-human tau antibody - Orphan - EMEA-002226-PIP02-17

AbbVie Ltd; Progressive Supranuclear Palsy

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Humanized recombinant IgG4 anti-human tau antibody for all subsets of the paediatric population (0 to 18 years of age) in the condition of Progressive Supranuclear Palsy.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.8. Enfortumab vedotin - EMEA-002299-PIP01-17

Astellas Pharma Europe B.V.; Treatment of locally advanced or metastatic urothelial cancer

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO's view expressed at D30 was re-discussed and endorsed.
Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for enfortumab vedotin for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of urothelial carcinoma' based on the ground 'that the medicinal product does not represent a significant therapeutic benefit' in the paediatric population. According to the data available Nectin-4 expression levels in paediatric tumours is very low meaning that the product may not be of benefit in the rare cases of urothelial tumours occurring in the paediatric population.

2.1.9. Polatuzumab vedotin - EMEA-002255-PIP01-17

Roche Registration Limited; Treatment of Diffuse Large B-Cell lymphoma (DLBCL), Treatment of Burkitt lymphoma, Burkitt leukemia (BL/B-ALL), Treatment of Follicular lymphoma (FL)

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO at their February 2018 meeting noted the clarifications received by the applicant and agreed on a waiver for polatuzumab vedotin for the condition treatment of mature B cell lymphomas on the grounds of lack of significant therapeutic benefit for all subsets of the paediatric population.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.10. Rovalpituzumab tesirine - Orphan - EMEA-002292-PIP01-17

AbbVie Ltd; Treatment of lung carcinoma (small cell and non-small cell carcinoma)

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO's view expressed at D30 was re-discussed. The Committee agreed with the requested product specific waiver for rovalpituzumab tesirine for the treatment of lung carcinoma (small cell and non-small cell carcinoma) based on the ground of the disease not occurring in children.

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for rovalpituzumab tesirine for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of lung carcinoma (small cell and non-small cell carcinoma) based on the ground of the disease not occurring in the paediatric population.

2.1.11. Calcium,N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes - EMEA-002293-PIP01-17

PledPharma AB; Oxaliplatin induced peripheral neuropathy (CIPN)

Day 60 opinion

Other / Oncology

Summary of committee discussion:

The PDCO acknowledged the applicant's responses to the D30 issues.

The Committee adopted an opinion by majority of 25 out of 26 votes. The Norwegian Member was in agreement with the Committee recommendation. The divergent position (Peter Sisovsky, SK) was appended to this opinion.

The PDCO recommends granting a waiver for Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese

complexes for all subsets of the paediatric population (0 to 18 years of age) in the condition of Oxaliplatin induced peripheral neuropathy.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Belatacept - EMEA-C3-000157-PIP01-07-M03

Bristol-Myers Squibb Pharma EEIG; Prevention of rejection of transplanted kidney

Day 60 letter

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO's view expressed at D30 was endorsed.
The completed study was considered to have been completed in compliance with the latest Agency's Decision (P/0002/2017) of 12/01/2017.
The PDCO finalised on 23 February 2018 this partially completed compliance procedure.

2.2.2. Tocilizumab - EMEA-C-000309-PIP01-08-M07

Roche Registration Limited; Chronic Idiopathic Arthritis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The completed study was checked for compliance and was considered compliant with the PDCO opinion.
The PDCO took note of preceding procedures and reports on partially completed compliance (partially completed EMEA-C1-000309-PIP01-08-M03; EMEA-C2-000309-PIP01-08-M05; EMEA-C3-000309-PIP01-08-M07).
The PDCO adopted on 23/2/2018 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0266/2015) of 27/11/2015.

2.2.3. Crisaborole - EMEA-C2-002065-PIP01-16

Pfizer Limited; Treatment of atopic dermatitis

Day 30 letter

Dermatology

Summary of committee discussion:

The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision (P/0338/2017) of 10 November 2017.
The PDCO finalised on 21 February 2018 this partially completed compliance procedure.

2.2.4. Fc- and CDR-modified humanised monoclonal antibody against C5 - EMEA-C1-002077-PIP01-16-M01

Alexion Europe SAS; Treatment of Paroxysmal Nocturnal Haemoglobinuria

Day 30 letter

Haematology-Hemostaseology

Summary of committee discussion:

The completed study was checked for compliance. The PDCO discussed the completed study, including the information submitted by the applicant between Day 30 and Day 60, and considered that it is compliant with the latest Agency's Decision (P/0356/2017) of 01/12/2017.
The PDCO finalised on 13/02/2018 this partially completed compliance procedure.

2.2.5. Glutamine - EMEA-C1-001996-PIP02-16

Emmaus Medical Europe Ltd; Treatment of sickle cell disease

Day 1 letter

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO considered that these Studies are compliant with the latest Agency's Decision (P/0003/2018) of 04 January 2018.
The PDCO finalised on 23 February 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.6. Brentuximab vedotin - EMEA-C3-000980-PIP01-10-M05

Takeda Pharma A/S; Treatment of Hodgkin lymphoma

Day 30 letter

Oncology

Summary of committee discussion:

The PDCO discussed the agreed initiation date and considered that it is compliant with the latest Agency's Decision (P/0232/2017) of 11 August 2017.
The PDCO finalised on 23 February 2018 this partially completed compliance procedure and confirmed the compliance of all those measures contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.7. Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage - EMEA-C2-001782-PIP01-15-M02

Abbott Biologicals B.V.; Prevention of influenza infection

Day 30 letter

Vaccines

Summary of committee discussion:

The completed study was checked for compliance. The PDCO discussed the completed study and considered that this is compliant with the latest Agency's Decision (P/0044/2018) of 16 February 2018.
The PDCO finalised on 20 February 2018 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.8. Dasatinib (as monohydrate) - EMEA-C-000567-PIP01-09-M05

Bristol-Myers Squibb Pharma EEIG; Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia

Day 1 opinion

Oncology

Summary of committee discussion:

The PDCO adopted on 23 February 2018 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0042/2018) of 16 February 2018.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Dopamine - EMEA-001105-PIP01-10-M04

BrePco Biopharma Limited; Treatment of vascular hypotensive disorders / Treatment of hypotension in neonates including the extremely low gestational age newborn / Treatment of hypotension in infants and children

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP

as set in the Agency's latest decision (P/0123/2017 of 5 May 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Evolocumab - EMEA-001268-PIP01-12-M05

Amgen Europe B.V.; Treatment of mixed dyslipidaemia, Treatment of elevated cholesterol / Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolaemia (HoFH) after Prior Lipid-Lowering Therapy in paediatric subjects aged 10 years and above

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0101/2017 of 11 April 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Crisaborole - EMEA-002065-PIP01-16-M01

Pfizer Ltd; Mild to moderate atopic dermatitis

Day 60 opinion

Dermatology

Summary of committee discussion:

The PDCO re-discussed the modification request taking into account the additional information and justification submitted by the applicant.
The Committee agreed with the requested modifications.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0338/2017 of 10 November 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Tilmanocept - EMEA-001255-PIP01-11-M03

Norgine BV; Visualisation of lymphatic drainage of solid tumours for diagnostic purposes / Visualisation of lymphatic drainage of rhabdomyosarcoma and melanoma for diagnostic purposes

Day 60 opinion

Diagnostic / Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, including the additional clarifications received since day 30, the PDCO considered that the proposed changes could be accepted.
The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Vedolizumab - EMEA-000645-PIP01-09-M06

Takeda Pharma A/S; Crohn's Disease, Ulcerative colitis

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The responses to the D30 issues were acknowledged.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0146/2017 of 7 June 2017).

2.3.6. Luspatercept - Orphan - EMEA-001521-PIP01-13-M02

Celgene Europe Ltd; Anemias due to chronic disorders / Treatment of anemia in patients with b-thalassemia

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO re-discussed this procedure during the February 2018 plenary.
The PDCO took into consideration the additional information the applicant provided after day 30.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan and on the discussion, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0219/2017 of 9 August 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Abatacept - EMEA-000118-PIP02-10-M03

Bristol-Myers Squibb Pharma EEIG; Chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthitis)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO re-discussed the views expressed on day 30, taking into account the applicant's clarifications. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0128/2014 of 22/05/2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Dalbavancin - EMEA-000016-PIP01-07-M06

Allergan Pharmaceuticals International Limited; Treatment of acute bacterial skin and skin structure infections

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO discussed at their February 2018 meeting the information received by the applicant in response to the D30 minutes.

In conclusion, based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0056/2016 of 18/3/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Nusinersen - Orphan - EMEA-001448-PIP01-13-M03

Biogen Idec Ltd; Treatment of spinal muscular atrophy

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0251/2016 of 23 September 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO

Opinion.

2.3.10. Peginterferon beta-1a - EMEA-001129-PIP01-11-M02

Biogen Idec Ltd; Treatment of relapsing remitting forms of Multiple Sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO confirmed most of the conclusions of the Day 30 discussion.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0040/2015 of 06 March 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Ponesimod - EMEA-000798-PIP01-09-M01

Actelion Registration Ltd; Treatment of multiple Sclerosis / Relapsing Remitting forms of Multiple Sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0286/2012 of 23 November 2012).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.12. Autologous CD4+ and CD8+ T cells Expressing a CD19-Specific Chimeric Antigen Receptor - Orphan - EMEA-001995-PIP01-16-M01

Celgene Europe Limited; Treatment of B-lymphoblastic leukemia/lymphoma, Treatment of mature B-cell neoplasms / Treatment of paediatric patients with CD19+ relapsed or refractory B-cell acute lymphoblastic leukaemia, Treatment of paediatric patients with CD19+ relapsed or refractory diffuse-large B-cell lymphoma, Burkitt lymphoma or primary mediastinal large B-cell lymphoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO took into consideration the clarifications provided by the applicant. Based on

the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0287/2017 of 4 October 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Quizartinib - Orphan - EMEA-001821-PIP01-15-M01

Daiichi Sankyo Europe GmbH; Treatment of acute myeloid leukaemia / For the treatment of paediatric patients aged from 1 month to less than 18 years of age with newly diagnosed AML with FLT3-ITD mutations., For the treatment of paediatric patients aged from 1 month to less than 18 years of age with refractory or relapsed AML with FLT3-ITD mutations after failure of front line intensive chemotherapy regimen, in combination with standard chemotherapy.

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO's view expressed at D30 was endorsed.
The clarification provided by the applicant after D30 was noted.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0203/2016 of 22/07/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Andexanet alfa - EMEA-001902-PIP01-15-M02

Portola Pharma UK Limited; Prevention of factor Xa inhibitor associated haemorrhage, treatment of factor Xa inhibitor associated haemorrhage / For the reversal of anticoagulation due to direct and indirect factor Xa inhibitors in patients requiring urgent surgery, For the reversal of anticoagulation due to direct and indirect factor Xa inhibitors in patients experiencing an acute major bleeding episode

Day 60 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0307/2017 of 30 October 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.15. Concentrate of proteolytic enzymes in bromelain - Orphan - EMEA-000142-PIP02-09-M06

MediWound Germany GmbH; Treatment of burns of external body surfaces / Removal of eschar in deep partial and/or full thickness burns

Day 60 opinion

Other

Summary of committee discussion:

The PDCO re-discussed the application including the information received since Day 30 and the assessors' comments.
A negative opinion refusing the requested changes has been adopted, the PIP requirements remain unchanged.

2.3.16. Palovarotene - Orphan - EMEA-001662-PIP01-14-M02

Clementia Pharmaceuticals Inc.; Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Day 60 opinion

Other

Summary of committee discussion:

The PDCO re-discussed this procedure during the February 2018 plenary.
The Committee considered that the plan was agreeable.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0364/2017 of 1 December 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Methoxyflurane - EMEA-000334-PIP01-08-M07

Medical Developments UK Ltd; Treatment of acute pain: 1. Self-administration to conscious patients with minor trauma and associated pain, under supervision of personnel trained in its use 2. Management of acute pain associated with short surgical procedures, such as the change of dressings, dislocations and injections

Day 60 opinion

Pain

Summary of committee discussion:

The PDCO re-considered the conclusions reached at day 30 and found them correct, not to be changed.
It was noted that the applicant submitted a new proposal after day 30, and it was presented to the Committee.
The PDCO adopted a positive opinion on the modification of the agreed PIP The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Tapentadol - EMEA-000325-PIP01-08-M09

Grünenthal GmbH; Treatment of chronic pain

Day 60 opinion

Pain

Summary of committee discussion:

The PDCO views expressed at day 30 were re-discussed, taking into account the applicant's additional information. The committee agreed that the proposed changes could be agreed.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0318/2017 of 31 October 2017). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.19. Benralizumab - EMEA-001214-PIP01-11-M07

AstraZeneca AB; Asthma

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0213/2016 of 12 August 2016). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.20. Lanadelumab - Orphan - EMEA-001864-PIP01-15-M02

Shire Pharmaceuticals Ireland Limited; Hereditary angioedema / Treatment of hereditary angioedema

Day 1 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0378/2017 of 01/12/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

2.4.1. Midostaurin - Orphan - EMEA-000780-PIP01-09-M04

Novartis Europharm Ltd; C92.0 Acute myeloid leukaemia, C94.3 Mast cell leukaemia, C96.2 Malignant mastocytosis / Treatment of paediatric patients with FLT3 mutated AML, newly diagnosed

Day 30 opinion

Oncology

Summary of committee discussion:

The Applicant requested a re-examination of the Opinion. At the oral explanation the Applicant presented their position.

In conclusion, taking into account the argumentation and further clarifications provided by the Applicant during the discussion, the PDCO considered that the proposed plan could be considered agreeable.

PDCO conclusion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan and the grounds for re-examination, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0011/2017 of 31 January 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Palonosetron / fosnetupitant - EMEA-001198-PIP03-17

Prevention of Chemotherapy-Induced Nausea and Vomiting

Day 90 discussion

Other

3.1.2. Neladenoson bialanate - EMEA-002262-PIP01-17

Treatment of Heart Failure

Day 60 discussion

Cardiovascular Diseases

3.1.3. EMEA-002287-PIP01-17

Treatment of Type 2 Diabetes Mellitus

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.4. EMEA-002310-PIP01-17

Treatment of paroxysmal nocturnal haemoglobinuria

Day 60 discussion

Haematology-Hemostaseology

3.1.5. Baricitinib - EMEA-001220-PIP04-17

Treatment of systemic lupus erythematosus

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.6. Recombinant IgG degrading enzyme of Streptococcus pyogenes - Orphan - EMEA-002183-PIP01-17

Hansa Medical AB; Patients with chronic kidney disease in need of kidney transplantation / Prevention of graft rejection following solid organ transplantation

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.7. Aztreonam / Avibactam sodium - EMEA-002283-PIP01-17

Infections caused by Gram-negative bacteria, including those that produce metallo-β-lactamases, for which there are limited or no treatment options. / For the treatment of complicated urinary tract infections, For the treatment of Ventilator associated pneumonia, For the treatment of complicated intra-abdominal infections, For the treatment of hospital-acquired pneumonia

Day 60 discussion

Infectious Diseases

3.1.8. Ridinilazole - EMEA-002250-PIP02-17

Treatment of Clostridium difficile Infection (CDI) and reducing the recurrence of CDI

Day 60 discussion

Infectious Diseases

3.1.9. Tafenoquine - EMEA-002301-PIP01-17

Prevention of malaria

Day 60 discussion

Infectious Diseases

3.1.10. Allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes - Orphan - EMEA-002025-PIP03-17

Atara Biotherapeutics, Inc.; Treatment of Epstein-Barr virus associated lymphoproliferative diseases in patients with primary immune disorders

Day 60 discussion

Oncology

3.1.11. Ipilimumab / nivolumab - EMEA-002049-PIP01-16

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)/Treatment of patients with unresectable or metastatic melanoma in the age group from 12 to less than 18 years old / Treatment of a paediatric malignant solid tumour in paediatric patients from 6 months to less than 18 years old

Day 60 discussion

Oncology

3.1.12. Ivosidenib - EMEA-002247-PIP02-17

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of the central nervous system / Treatment of paediatric patients (2 to less than 18 years of age) with recurrent or progressive (R/P) malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms), including central nervous system tumours, with an isocitrate dehydrogenase-1 (IDH1) mutation.

Day 60 discussion

Oncology

3.1.13. Ivosidenib - Orphan - EMEA-002247-PIP03-17

Agios Pharmaceuticals, Inc.; Treatment of Acute Myeloid Leukaemia / Treatment of paediatric patients from 2 to less than 18 years of age with newly diagnosed and relapsed or refractory (R/R) AML with an isocitrate dehydrogenase-1 (IDH1) mutation

Day 60 discussion

Oncology

3.1.14. Olaparib - Orphan - EMEA-002269-PIP01-17

AstraZeneca AB; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system [CNS], haematopoietic, and lymphoid tissue). / Treatment of paediatric patients from 6 months to ≤18 years old with homologous recombination repair (HRR) mutated solid tumours

Day 60 discussion

Oncology

3.1.15. Recombinant human acid ceramidase - Orphan - EMEA-002266-PIP01-17

Enzyvant Farber Ireland Ltd; Farber disease

Day 60 discussion

Other

3.1.16. Olodanrigan - EMEA-002286-PIP01-17

Treatment of moderate to severe peripheral neuropathic pain

Day 60 discussion

Pain

3.1.17. EMEA-002310-PIP02-17

Treatment of C3 glomerulopathy

Day 60 discussion

Uro-nephrology

3.1.18. Ferric Pyrophosphate Citrate - EMEA-002261-PIP01-17

Treatment of iron deficient anaemia in haemodialysis patients

Day 60 discussion

Uro-nephrology / Haematology-Hemostaseology

3.1.19. Etripamil - EMEA-002303-PIP01-17

Treatment of acute paroxysmal supraventricular tachycardia (PSVT)

Day 30 discussion

Cardiovascular Diseases

3.1.20. Irbesartan / Amlodipine - EMEA-002192-PIP02-17

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine and irbesartan taken as two single-component formulations

Day 30 discussion

Cardiovascular Diseases

3.1.21. EMEA-002312-PIP01-17

Treatment of moderate to severe atopic dermatitis inadequately responsive to topical therapies or where topical treatments are not appropriate

Day 30 discussion

Dermatology

3.1.22. EMEA-001710-PIP04-17

Treatment of Crohn's disease

Day 30 discussion

Gastroenterology-Hepatology

3.1.23. Cenicriviroc - EMEA-001999-PIP02-17

NASH with Stage 2-3 fibrosis

Day 30 discussion

Gastroenterology-Hepatology

3.1.24. Dusquetide - EMEA-002306-PIP01-17

Treatment of Oral Mucositis

Day 30 discussion

Gastroenterology-Hepatology

3.1.25. Fluticasone propionate - Orphan - EMEA-002289-PIP01-17

Adare Pharmaceuticals; eosinophilic esophagitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.26. Hepcidin-25 acetate (synthetic human hepcidin) - Orphan - EMEA-002083-PIP01-16

La Jolla Pharmaceutical II B.V.; Treatment of iron overload

Day 30 discussion

Haematology-Hemostaseology

3.1.27. Human monoclonal IgG1 antibody against Tissue Factor Pathway Inhibitor - Orphan - EMEA-002285-PIP01-17

Pfizer Limited; Treatment of coagulation disorders congenital

Day 30 discussion

Haematology-Hemostaseology

3.1.28. Voclosporin - EMEA-002264-PIP01-17

Treatment of Systemic Lupus Erythematosus / Treatment of Active Lupus Nephritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.29. Upadacitinib Hemihydrate - EMEA-001741-PIP04-17

Treatment of Atopic Dermatitis

Day 30 discussion

Immunology-Rheumatology-Transplantation / Dermatology

3.1.30. Brincidofovir - Orphan - EMEA-001904-PIP02-17

Chimerix UK Limited; Treatment of AdV in immunocompromised patients

Day 30 discussion

Infectious Diseases

3.1.31. Tenofovir Alafenamide / Emtricitabine - EMEA-001577-PIP03-17

Prevention of human immunodeficiency virus (HIV-1) infection / In combination with safer sex practices for prevention of HIV-1 infection in adolescents aged 12 years and above

Day 30 discussion

Infectious Diseases

3.1.32. Evobrutinib - EMEA-002284-PIP01-17

Treatment of Multiple Sclerosis

Day 30 discussion

Neurology

3.1.33. Sarizotan Hydrochloride - Orphan - EMEA-001808-PIP03-17

Newron Pharmaceuticals SpA; Treatment of Rett Syndrome

Day 30 discussion

Neurology

3.1.34. Immunoglobulin G4 - EMEA-002290-PIP01-17

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) / in combination with nivolumab for the treatment of malignant solid tumours in paediatric patients from 6 months to less than 18 years old.

Day 30 discussion

Oncology

3.1.35. Diphtheria Toxin Interleukin-3 Fusion Protein - Orphan - EMEA-002244-PIP01-17

Stemline Therapeutics, Inc.; Treatment of all conditions included in the category of myeloid and lymphoid neoplasms expressing CD123.

Day 30 discussion

Oncology

3.1.36. Xentuzumab - EMEA-002228-PIP01-17

Breast malignant neoplasms

Day 30 discussion

Oncology

3.1.37. EMEA-002291-PIP01-17

Treatment of dry eye disease

Day 30 discussion

Ophthalmology

3.1.38. Ranibizumab - EMEA-000527-PIP05-17

Diabetic retinopathy (DR)

Day 30 discussion

Ophthalmology

3.1.39. Clostridium botulinum neurotoxin type A - EMEA-001039-PIP03-17

Treatment of hemifacial spasm

Day 30 discussion

Ophthalmology / Neurology

3.1.40. Ibuprofen / paracetamol - EMEA-002002-PIP02-17

Fever, unspecified, Pain, unspecified

Day 30 discussion

Other / Pain

3.1.41. Molgramostim - Orphan - EMEA-002282-PIP01-17

Savara ApS; Treatment of children from 2 to less than 18 years with secondary

pulmonary alveolar proteinosis, Treatment of children from 2 to less than 18 years with autoimmune pulmonary alveolar proteinosis

Day 30 discussion

Pneumology - Allergology

3.1.42. Eszopiclone - EMEA-002309-PIP01-17

F51.0

Day 30 discussion

Psychiatry

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Dabigatran etexilate mesilate - EMEA-C3-000081-PIP01-07-M10

Boehringer Ingelheim International GmbH; Treatment of thromboembolic events

Day 30 discussion

Cardiovascular Diseases / Haematology-Hemostaseology

3.2.2. Ibrutinib - EMEA-C2-001397-PIP03-14-M03

Janssen-Cilag International N.V.; Treatment of mature B-cell neoplasm

Day 30 discussion

Oncology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Angiotensin II - EMEA-001912-PIP02-16-M01

La Jolla Pharmaceutical II B.V.; Hypotension associated with distributive or vasodilatory shock

Day 30 discussion

Cardiovascular Diseases

3.3.2. Treprostinil - EMEA-000207-PIP01-08-M06

Ferrer Internacional, S.A.; Treatment of pulmonary arterial hypertension

Day 30 discussion

Cardiovascular Diseases

3.3.3. Edoxaban (tosylate) - EMEA-000788-PIP02-11-M07

Daiichi Sankyo Europe GmbH; Prevention of arterial thromboembolism, Prevention of venous thromboembolism, Treatment of venous thromboembolism / Prevention of arterial thromboembolism in paediatric cardiac patients at risk of thrombotic events, Acute treatment & secondary prevention of symptomatic recurrent venous thrombotic events (VTE) in paediatric patients at risk

Day 30 discussion

Cardiovascular Diseases / Haematology-Hemostaseology

3.3.4. Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia cupana Kunth, Theobroma cacao L. - EMEA-001835-PIP01-15-M03

LEGACY HEALTHCARE; Treatment of alopecia

Day 30 discussion

Dermatology

3.3.5. Testosterone - EMEA-001529-PIP02-14-M01

Acerus Biopharma Inc.; Treatment of male hypogonadism

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Guselkumab - EMEA-001523-PIP02-14-M02

Janssen Cilag International NV; Treatment of severe plaque psoriasis in children ≥6 to <18 years of age who cannot be adequately controlled with topical agents and/or phototherapy

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.7. Peginterferon alfa-2a - EMEA-000298-PIP01-08-M06

Roche Registration Ltd; Treatment of Chronic Hepatitis C in combination with other agent(s), Treatment of chronic hepatitis B

Day 30 discussion

Infectious Diseases

3.3.8. Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M05

GW Pharma Ltd; Spasticity / Intractable spasticity due to cerebral palsy or traumatic CNS injury

Day 30 discussion

Neurology

3.3.9. Galcanezumab - EMEA-001860-PIP03-16-M01

Eli Lilly and Company Limited; Prevention of migraine headaches

Day 30 discussion

Neurology

3.3.10. Inebilizumab - Orphan - EMEA-001911-PIP01-15-M01

MedImmune, LLC (affiliate of AstraZeneca); neuromyelitis optica (NMO) or NMO spectrum disorders (NMOSD)

Day 30 discussion

Neurology

3.3.11. Sunitinib malate - EMEA-000342-PIP01-08-M07

Pfizer Limited; CD10 code C49.4 malignant neoplasms of connective and soft tissue of abdomen - gastro-intestinal stromal tumours (GIST) / Treatment of gastro-intestinal stromal tumour in paediatric patients aged 6 to less than 18

Day 30 discussion

Oncology

3.3.12. Naloxone hydrochloride - EMEA-001567-PIP01-13-M03

Develco Pharma GmbH; Treatment of opioid-induced constipation

Day 30 discussion

Other / Pain / Gastroenterology-Hepatology

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 02 May 2018 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. fixed combination with apalutamide and abiraterone acetate- EMEA-20-2017

Janssen-Cilag International N.V; The classes of androgen receptor modulator, of growth and sex hormone as well as their releasing or inhibiting factors, and of sex hormone-metabolism modulator medicinal products for treatment of prostate malignant neoplasms / Treatment of metastatic castration resistant prostate cancer that has progressed after treatment with GnRHa or orchiectomy in combination with prednisone

and ADT (GnRHa or orchiectomy).

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

6.1.2. Budesonide, glycopyrronium bromide, formoterol fumarate dihydrate - EMEA-01-2018

AstraZeneca AB; All classes of medicinal products for treatment of chronic obstructive pulmonary disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft-versus-host disease after [bone-marrow] transplantation)/ Maintenance treatment of patients with moderate to severe COPD

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: treatment of asthma.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

None

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. New synchronised submission deadlines and submission guidance

Summary of committee discussion:

The revised 2018 and new 2019 - 2021 submission deadlines have been published on the EMA website and the new Guidance on paediatric submissions is now available in the eSubmission website.

The use of the eSubmission Gateway and/or the Web Client became mandatory for all paediatric applications from 1 January 2018. To allow applicant to adapt to the new submission requirements, EMA will allow a transition period until 15 March 2018. After that date, the European Medicines Agency (EMA) will no longer accept submissions by Eudralink. Applicants are not expected to send paediatric submissions to appointed rapporteurs and peer reviewers any longer.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in January 2018 was presented to the PDCO members.

The members were also informed about 2 medicinal products, Hemlibra and Lamzede for which the CHMP adopted a positive opinion recommending a paediatric indication during their meeting in January 2018.

9.2.1.1. Joint CHMP/PDCO session

Summary of committee discussion:

A topic relating to paediatric oncology was discussed.

9.2.2. Committee for Medicinal Products for Human Use (CHMP)

Estimands

CHMP member: Robert Hemmings

Summary of committee discussion:

A presentation was held on the estimand framework in the context of clinical trials. The choice of estimands was illustrated with a real world example.

Coordination with EMA Working Parties / Working Groups / Drafting Groups

9.2.3. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.

9.2.4. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.2.5. Guideline on the clinical investigation of recombinant and 4 human plasma-derived factor VIII products

Summary of committee discussion:

The PDCO has been informed on the envisaged next steps as regards the “Revision of Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products”, following the preliminary evaluation of the comments from the public consultation phase which ended on 31 January 2018.

9.2.6. Q&A on paediatric aspects on the use of modelling and simulation in paediatric development

Postponed

9.3. Cooperation within the EU regulatory network

9.3.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

None

9.3.2. European Directorate for the Quality of Medicines and HealthCare (EDQM)

PDCO member: Siri Wang

Summary of committee discussion:

The Committee was updated on the EDQM Paediatric Formulary project for

extemporaneous formulations and was informed on the principle on which the project is based and how the work on the project is proceeding.

9.4. Cooperation with International Regulators

None

9.5. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.6. PDCO work plan

None

9.7. Planning and reporting

None

10. Any other business

10.1. AOB topic

10.1.1. Multi-stakeholder workshop to further improve the implementation of the paediatric regulation

Summary of committee discussion:

The committee was informed of organisational aspects of the upcoming workshop. Moreover, the committee discussed and agreed on the objectives of the workshop.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed planned activities and upcoming events in 2018.

11.1.2. Neonatology

Summary of committee discussion:

The group discussed ongoing activities, including procedures with impact on the development of medicinal products in neonates.

11.1.3. Inventory

Summary of committee discussion:

The inventory group convened to progress with the discussion on assessment of unmet needs.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 20 – 23 February 2018 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	No restrictions applicable to this meeting	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Adriana Andrić	Member	Croatia	No interests declared	
Suzana Mimica Matanovic	Alternate	Croatia	No interests declared	
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Kirstine Moll Harboe	Member	Denmark	No interests declared	
Ann Marie Kaukonen	Member	Finland	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	

Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting		
Goda Vaitkeviciene	Alternate	Lithuania	No interests declared		
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared		
Herbert Lenicker	Alternate	Malta	No interests declared		
Maaike van Dartel	Member	Netherlands	No interests declared		
Siri Wang	Member	Norway	No interests declared		
Anette Solli Karlsen	Alternate	Norway	No interests declared		
Marek Migdal	Member	Poland	No interests declared		
Helena Fonseca	Member	Portugal	No interests declared		
Hugo Tavares	Alternate	Portugal	No interests declared		
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared		
Peter Sisovsky	Member	Slovakia	No interests declared		
Stefan Grosek	Member	Slovenia	No interests declared		
Fernando de Andrés Trelles	Member	Spain	No interests declared		
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared		
Ninna Gullberg	Member	Sweden	No interests declared		
Angeliki Siapkara	Member	United Kingdom	No interests declared		
Martina Riegl	Alternate	United Kingdom	No interests declared		
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared		
Riccardo Riccardi	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting		
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting		

Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared		
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting		
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared		
Viviana Giannuzzi	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting		
Robert James Hemmings	Expert - in person*	CHMP Member	No interests declared		
Paula Boudewina van Hennik	Expert - in person*	CHMP Member	No interests declared		
Catriona Elisabeth Baker	Expert - in person*	United Kingdom	No interests declared		
Eleni Gaki	Expert - in person*	United Kingdom	No interests declared		
Swati Bhat	Expert - in person*	United Kingdom	No interests declared		
Shiva Ramroop	Expert - in person*	United Kingdom	No restrictions applicable to this meeting		
Meeting run with support from relevant EMA staff					

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website:
www.ema.europa.eu/